Introduction
PCOS, polycystic ovary syndrome, overweight PCOS, hyperandrogenism, weight loss, reproductive dysfunction
HYPERINSULINISM, POLYCYSTIC OVARY SYNDROME, HYPERGLYCEMIA, METABOLIC DISORDERS, POLYCYSTIC OVARY SYNDROME, HYPERANDROGENISM, INSULIN SENSITIVITY
Polycystic ovary syndrome (PCOS) is a common cause of female reproductive dysfunction [Currently, the pharmacological therapy of PCOS includes oral contraceptives, insulin sensitizers, weight-loss drugs, and ovulation induction agents. A number of monotherapies have been used to treat overweight PCOS patients, but it is hard to improve both hyperandrogenism and metabolic disorders. Hormonal contraceptives, such as co-cyprindiol (cyproterone acetate/ethinylestradiol, CPA/EE) consisting of 2 mg cyproterone acetate (CPA) and 35 μg ethinylestradiol (EE), are recommended for the management of PCOS patients with hyperandrogenism [Metformin is widely used to treat hyperglycemia, hyperinsulinism, and even hyperandrogenism through improving glucose uptake and insulin sensitivity [However, there are few reports on the effects of GLP-1RA combined with metformin on glucose and lipid metabolism and reproductive function in PCOS patients. We hypothesized that the GLP-1RA +Met has better efficacy in reducing weight loss and improving glucose and lipid metabolism and reproduction in PCOS patients. Thus, we evaluated the efficacy of GLP-1RA + Met in the treatment of weight, metabolic and endocrine parameters in overweight women with polycystic ovary syndrome through clinical trials, and we further performed plasma proteomics profiling to explore potential mechanisms and to identify biomarkers of therapeutic effectiveness. Finally, We present the following article in accordance with the CONSORT reporting checklist.